What is HC Wainwright’s Estimate for NovoCure Q1 Earnings?

NovoCure Limited (NASDAQ:NVCR) – Analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for shares of NovoCure in a research note issued on Thursday, February 12th. HC Wainwright analyst E. Bodnar now expects that the medical equipment provider will post earnings of ($0.54) per share for the quarter, down from their prior forecast of ($0.50). HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for NovoCure’s Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($1.90) EPS, FY2027 earnings at ($1.30) EPS, FY2028 earnings at ($0.25) EPS, FY2029 earnings at $1.58 EPS and FY2030 earnings at $4.25 EPS.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. JPMorgan Chase & Co. dropped their target price on shares of NovoCure from $25.00 to $23.00 and set a “neutral” rating on the stock in a research report on Monday, October 27th. Wedbush reiterated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a research note on Thursday, January 15th. Finally, Evercore set a $20.00 price target on shares of NovoCure in a research report on Monday, January 5th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $26.64.

NovoCure Price Performance

Shares of NASDAQ NVCR opened at $10.99 on Monday. The stock’s 50-day simple moving average is $12.88 and its 200-day simple moving average is $12.61. The firm has a market capitalization of $1.23 billion, a PE ratio of -6.83 and a beta of 0.73. NovoCure has a fifty-two week low of $9.82 and a fifty-two week high of $22.95. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55.

Institutional Trading of NovoCure

Institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC grew its position in NovoCure by 56.7% during the 1st quarter. AQR Capital Management LLC now owns 28,728 shares of the medical equipment provider’s stock worth $512,000 after purchasing an additional 10,394 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of NovoCure by 3.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider’s stock worth $1,336,000 after buying an additional 2,502 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of NovoCure by 5.5% during the first quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider’s stock worth $17,707,000 after buying an additional 52,180 shares during the last quarter. Acadian Asset Management LLC acquired a new position in NovoCure in the 1st quarter valued at about $87,000. Finally, KLP Kapitalforvaltning AS raised its stake in NovoCure by 6.5% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 23,000 shares of the medical equipment provider’s stock valued at $409,000 after acquiring an additional 1,400 shares during the last quarter. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure News Summary

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: FDA approval expands commercial opportunity — The U.S. FDA cleared Optune Pax for locally advanced pancreatic cancer, giving NovoCure a new approved indication that could materially broaden TTFields usage beyond brain tumors and boost future revenue. Novocure wins FDA nod for Optune Pax as pancreatic cancer treatment
• Positive Sentiment: Big near-term market reaction — Multiple outlets report the stock surged sharply (20–30%+) on the approval, reflecting strong investor enthusiasm for the new indication. That buying lifted visibility and trading volume. NovoCure (NVCR) Is Up 23.6% After Landmark FDA Nod For Optune Pax In Pancreatic Cancer
• Positive Sentiment: Longer-term expansion case highlighted by analysts — Commentary and analysis point to a meaningful addressable‑market expansion if adoption and reimbursement follow, supporting a larger revenue runway over several years. NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching
• Neutral Sentiment: Valuation and modeling questions remain — Coverage is focusing on how to value the new indication, timing of uptake, and assumptions for pricing/reimbursement; investors are debating how much of the approval is already priced into the rally. Assessing NovoCure (NVCR) Valuation After FDA Approval Of Optune Pax For Pancreatic Cancer
• Neutral Sentiment: Broader market context influencing moves — Nasdaq/futures action and overall tape volatility have accentuated the stock’s intraday swings as macro flows and sector momentum interact with company‑specific news. Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Job Report—Micron, Novocure, Fastly In Focus
• Negative Sentiment: Profit‑taking and short‑term pullback — After the initial surge, some investors took profits and the stock pulled back; with elevated short‑term volatility, downside risk remains if adoption/reimbursement timelines disappoint or if broader selling resumes. What’s Happening With NovoCure Stock?

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.